What is the specific latest selling price of Avonib in China?

Ivosidenib (Ivosidenib) is an innovative anti-tumor drug targeting IDH1 mutations. It is mainly used to treat acute myeloid leukemia (AML) patients with IDH1 gene mutations. Its mechanism of action is to inhibit 2-hydroxyglutarate (2-HG) produced by the mutant IDH1 enzyme. This metabolite can block the normal differentiation of hematopoietic cells, leading to the occurrence of leukemia. Ivonib is a major breakthrough in the field of AML in recent years by reducing 2-HG levels, restoring the differentiation ability of hematopoietic cells, and achieving disease control.

According to the indications approved by the U.S. FDAivonib is suitable for adult patients with relapsed or refractory IDH1-mutated AML, and can also be used in combination with azacitidine for patients with IDH1-mutated AML who have been initially treated but are not suitable for intensive chemotherapy. Its efficacy has been confirmed in multiple international clinical trials. For example, the AG120-C-001 and AGILE studies have shown that ivonib can significantly prolong overall survival and duration of response, and to a certain extent, improve the outcomes of patients with poor prognosis of traditional treatments. In addition, the oral dosage form of the drug provides patients with a more convenient treatment path and has become one of the important choices for high-risk patients.

In China, the original research version of avosidenib will be officially launched in China in 2023. At present, the common specifications in the domestic market are 0.25g (250mg) * 60 tablets. Each box sells for about RMB 70,000. It has not yet been included in the national medical insurance catalog, so most patients still need to pay for it in full at their own expense. Compared with the international market, although this price has been controlled, it still poses a considerable burden to many ordinary families.

In order to alleviate the burden of high drug costs, some patients will also pay attention to the availability of overseas generic drugs. At present, Laos, Bangladesh and other countries have produced generic versions of ivonib. Most of these generic drugs are 250 mg × 60 tablets. The ingredients and dosage are consistent with the original drug, but the price is only more than 3,000 yuan per box, which greatly lowers the threshold for drug use. In particular, generic drugs produced in Laos have been proven to have high consistency in multiple international channels and are an important alternative for many patients with limited economic conditions.

Reference: https://www.tibsovo.com/